The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaGhayas C. Issa, Eytan M. Stein|Nature|2023Cited by 450
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D. DiNardo, Hagop M. Kantarjian, Guillermo Montalban‐Bravo et al.|Journal of Clinical Oncology|2021Cited by 333
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 InhibitorsAhmad S. Alotaibi, Naval Daver, Musa Yılmaz et al.|Blood Cancer Discovery|2020Cited by 97
Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaAmber Gibson, Branko Cuglievan, Adriana Trabal et al.|Cancers|2021Cited by 66